254 related articles for article (PubMed ID: 15961982)
1. Imaging P-glycoprotein transport activity at the human blood-brain barrier with positron emission tomography.
Sasongko L; Link JM; Muzi M; Mankoff DA; Yang X; Collier AC; Shoner SC; Unadkat JD
Clin Pharmacol Ther; 2005 Jun; 77(6):503-14. PubMed ID: 15961982
[TBL] [Abstract][Full Text] [Related]
2. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
3. Effect of age on functional P-glycoprotein in the blood-brain barrier measured by use of (R)-[(11)C]verapamil and positron emission tomography.
Toornvliet R; van Berckel BN; Luurtsema G; Lubberink M; Geldof AA; Bosch TM; Oerlemans R; Lammertsma AA; Franssen EJ
Clin Pharmacol Ther; 2006 Jun; 79(6):540-8. PubMed ID: 16765142
[TBL] [Abstract][Full Text] [Related]
4. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of (R)-[11C]verapamil as PET tracer of P-glycoprotein function in the blood-brain barrier: kinetics and metabolism in the rat.
Luurtsema G; Molthoff CF; Schuit RC; Windhorst AD; Lammertsma AA; Franssen EJ
Nucl Med Biol; 2005 Jan; 32(1):87-93. PubMed ID: 15691665
[TBL] [Abstract][Full Text] [Related]
6. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier.
Hendrikse NH; de Vries EG; Eriks-Fluks L; van der Graaf WT; Hospers GA; Willemsen AT; Vaalburg W; Franssen EJ
Cancer Res; 1999 May; 59(10):2411-6. PubMed ID: 10344751
[TBL] [Abstract][Full Text] [Related]
7. Imaging of cyclosporine inhibition of P-glycoprotein activity using 11C-verapamil in the brain: studies of healthy humans.
Muzi M; Mankoff DA; Link JM; Shoner S; Collier AC; Sasongko L; Unadkat JD
J Nucl Med; 2009 Aug; 50(8):1267-75. PubMed ID: 19617341
[TBL] [Abstract][Full Text] [Related]
8. Developmental changes in P-glycoprotein function in the blood-brain barrier of nonhuman primates: PET study with R-11C-verapamil and 11C-oseltamivir.
Takashima T; Yokoyama C; Mizuma H; Yamanaka H; Wada Y; Onoe K; Nagata H; Tazawa S; Doi H; Takahashi K; Morita M; Kanai M; Shibasaki M; Kusuhara H; Sugiyama Y; Onoe H; Watanabe Y
J Nucl Med; 2011 Jun; 52(6):950-7. PubMed ID: 21571790
[TBL] [Abstract][Full Text] [Related]
9. Imaging the impact of cyclosporin A and dipyridamole on P-glycoprotein (ABCB1) function at the blood-brain barrier: A [(11)C]-N-desmethyl-loperamide PET study in nonhuman primates.
Damont A; Goutal S; Auvity S; Valette H; Kuhnast B; Saba W; Tournier N
Eur J Pharm Sci; 2016 Aug; 91():98-104. PubMed ID: 27283486
[TBL] [Abstract][Full Text] [Related]
10. Modeling cyclosporine A inhibition of the distribution of a P-glycoprotein PET ligand, 11C-verapamil, into the maternal brain and fetal liver of the pregnant nonhuman primate: impact of tissue blood flow and site of inhibition.
Ke AB; Eyal S; Chung FS; Link JM; Mankoff DA; Muzi M; Unadkat JD
J Nucl Med; 2013 Mar; 54(3):437-46. PubMed ID: 23359659
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of in vivo P-glycoprotein function at the blood-brain barrier among MDR1 gene polymorphisms by using 11C-verapamil.
Takano A; Kusuhara H; Suhara T; Ieiri I; Morimoto T; Lee YJ; Maeda J; Ikoma Y; Ito H; Suzuki K; Sugiyama Y
J Nucl Med; 2006 Sep; 47(9):1427-33. PubMed ID: 16954549
[TBL] [Abstract][Full Text] [Related]
12. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of tracer kinetic models for quantification of P-glycoprotein function using (R)-[11C]verapamil and PET.
Lubberink M; Luurtsema G; van Berckel BN; Boellaard R; Toornvliet R; Windhorst AD; Franssen EJ; Lammertsma AA
J Cereb Blood Flow Metab; 2007 Feb; 27(2):424-33. PubMed ID: 16757979
[TBL] [Abstract][Full Text] [Related]
14. Modulation of P-glycoprotein at the Human Blood-Brain Barrier by Quinidine or Rifampin Treatment: A Positron Emission Tomography Imaging Study.
Liu L; Collier AC; Link JM; Domino KB; Mankoff DA; Eary JF; Spiekerman CF; Hsiao P; Deo AK; Unadkat JD
Drug Metab Dispos; 2015 Nov; 43(11):1795-804. PubMed ID: 26354948
[TBL] [Abstract][Full Text] [Related]
15. Regional increase in P-glycoprotein function in the blood-brain barrier of patients with chronic schizophrenia: a PET study with [(11)C]verapamil as a probe for P-glycoprotein function.
de Klerk OL; Willemsen AT; Bosker FJ; Bartels AL; Hendrikse NH; den Boer JA; Dierckx RA
Psychiatry Res; 2010 Aug; 183(2):151-6. PubMed ID: 20620031
[TBL] [Abstract][Full Text] [Related]
16. In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil.
Lee YJ; Maeda J; Kusuhara H; Okauchi T; Inaji M; Nagai Y; Obayashi S; Nakao R; Suzuki K; Sugiyama Y; Suhara T
J Pharmacol Exp Ther; 2006 Feb; 316(2):647-53. PubMed ID: 16293715
[TBL] [Abstract][Full Text] [Related]
17. Duration and degree of cyclosporin induced P-glycoprotein inhibition in the rat blood-brain barrier can be studied with PET.
Syvänen S; Blomquist G; Sprycha M; Höglund AU; Roman M; Eriksson O; Hammarlund-Udenaes M; Långström B; Bergström M
Neuroimage; 2006 Sep; 32(3):1134-41. PubMed ID: 16857389
[TBL] [Abstract][Full Text] [Related]
18. Locally increased P-glycoprotein function in major depression: a PET study with [11C]verapamil as a probe for P-glycoprotein function in the blood-brain barrier.
de Klerk OL; Willemsen AT; Roosink M; Bartels AL; Hendrikse NH; Bosker FJ; den Boer JA
Int J Neuropsychopharmacol; 2009 Aug; 12(7):895-904. PubMed ID: 19224656
[TBL] [Abstract][Full Text] [Related]
19. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
[TBL] [Abstract][Full Text] [Related]
20. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
